268 related articles for article (PubMed ID: 32677159)
1. Role of the MUC1-C oncoprotein in the acquisition of cisplatin resistance by urothelial carcinoma.
Shigeta K; Hasegawa M; Kikuchi E; Yasumizu Y; Kosaka T; Mizuno R; Mikami S; Miyajima A; Kufe D; Oya M
Cancer Sci; 2020 Oct; 111(10):3639-3652. PubMed ID: 32677159
[TBL] [Abstract][Full Text] [Related]
2. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
3. Nicotine Induces Tumor Growth and Chemoresistance through Activation of the PI3K/Akt/mTOR Pathway in Bladder Cancer.
Yuge K; Kikuchi E; Hagiwara M; Yasumizu Y; Tanaka N; Kosaka T; Miyajima A; Oya M
Mol Cancer Ther; 2015 Sep; 14(9):2112-20. PubMed ID: 26184482
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA‑22 mediates the cisplatin resistance of osteosarcoma cells by inhibiting autophagy via the PI3K/Akt/mTOR pathway.
Meng CY; Zhao ZQ; Bai R; Zhao W; Wang YX; Xue HQ; Sun L; Sun C; Feng W; Guo SB
Oncol Rep; 2020 Apr; 43(4):1169-1186. PubMed ID: 32323781
[TBL] [Abstract][Full Text] [Related]
5. Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells.
Raina D; Kosugi M; Ahmad R; Panchamoorthy G; Rajabi H; Alam M; Shimamura T; Shapiro GI; Supko J; Kharbanda S; Kufe D
Mol Cancer Ther; 2011 May; 10(5):806-16. PubMed ID: 21421804
[TBL] [Abstract][Full Text] [Related]
6. Akt confers cisplatin chemoresistance in human gynecological carcinoma cells by modulating PPM1D stability.
Ali AY; Kim JY; Pelletier JF; Vanderhyden BC; Bachvarov DR; Tsang BK
Mol Carcinog; 2015 Nov; 54(11):1301-14. PubMed ID: 25154814
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
[TBL] [Abstract][Full Text] [Related]
8. Transcribed ultraconserved region Uc.63+ promotes resistance to cisplatin through regulation of androgen receptor signaling in bladder cancer.
Sekino Y; Sakamoto N; Ishikawa A; Honma R; Shigematsu Y; Hayashi T; Sentani K; Oue N; Teishima J; Matsubara A; Yasui W
Oncol Rep; 2019 May; 41(5):3111-3118. PubMed ID: 30864720
[TBL] [Abstract][Full Text] [Related]
9. Targeting MUC1-C inhibits the AKT-S6K1-elF4A pathway regulating TIGAR translation in colorectal cancer.
Ahmad R; Alam M; Hasegawa M; Uchida Y; Al-Obaid O; Kharbanda S; Kufe D
Mol Cancer; 2017 Feb; 16(1):33. PubMed ID: 28153010
[TBL] [Abstract][Full Text] [Related]
10. PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathways.
Fu X; Feng J; Zeng D; Ding Y; Yu C; Yang B
Biosci Rep; 2014 Apr; 34(2):. PubMed ID: 27919028
[TBL] [Abstract][Full Text] [Related]
11. Silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K/Akt/mTOR signaling pathway.
Shi H; Pu J; Zhou XL; Ning YY; Bai C
Tumour Biol; 2017 May; 39(5):1010428317697568. PubMed ID: 28459375
[TBL] [Abstract][Full Text] [Related]
12. C-reactive protein promotes tongue squamous cell carcinoma chemoresistance by inhibiting the activation of caspase-3/9 via the CD64/AKT/mTOR pathway.
Yan X; Cao M; Wang Z; Wang S; Chen Q
Hum Cell; 2021 Sep; 34(5):1424-1433. PubMed ID: 34019244
[TBL] [Abstract][Full Text] [Related]
13. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD
Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094
[TBL] [Abstract][Full Text] [Related]
14. Glutathione Peroxidase 1 Promotes NSCLC Resistance to Cisplatin via ROS-Induced Activation of PI3K/AKT Pathway.
Chen B; Shen Z; Wu D; Xie X; Xu X; Lv L; Dai H; Chen J; Gan X
Biomed Res Int; 2019; 2019():7640547. PubMed ID: 31032363
[TBL] [Abstract][Full Text] [Related]
15. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of CD133 Overcomes Cisplatin Resistance Through Inhibiting PI3K/AKT/mTOR Signaling Pathway and Autophagy in CD133-Positive Gastric Cancer Cells.
Lu R; Zhao G; Yang Y; Jiang Z; Cai J; Hu H
Technol Cancer Res Treat; 2019 Jan; 18():1533033819864311. PubMed ID: 31405336
[TBL] [Abstract][Full Text] [Related]
17. [CA916798 gene participates in cisplatin resistance of human lung adenocarcinoma A549 cells through PI3K/AKT/mTOR pathway].
Qi Z; Wang Y; Zhou X
Nan Fang Yi Ke Da Xue Xue Bao; 2012 Sep; 32(9):1290-3. PubMed ID: 22985566
[TBL] [Abstract][Full Text] [Related]
18. Activation of PI3K/AKT/mTOR signaling axis by UBE2S inhibits autophagy leading to cisplatin resistance in ovarian cancer.
Zhang M; Wang J; Guo Y; Yue H; Zhang L
J Ovarian Res; 2023 Dec; 16(1):240. PubMed ID: 38115063
[TBL] [Abstract][Full Text] [Related]
19. Osthole promotes the suppressive effects of cisplatin on NRF2 expression to prevent drug-resistant cervical cancer progression.
Su J; Zhang F; Li X; Liu Z
Biochem Biophys Res Commun; 2019 Jun; 514(2):510-517. PubMed ID: 31056260
[TBL] [Abstract][Full Text] [Related]
20. Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: its potential use in the treatment of bladder cancers.
Houédé N; Pourquier P
Pharmacol Ther; 2015 Jan; 145():1-18. PubMed ID: 24929024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
